Gundersen S, Kvinnsland S, Klepp O, Lund E, Høst H
Hospital, Montebello, Oslo, Norway.
Eur J Cancer. 1990 Jan;26(1):45-8. doi: 10.1016/0277-5379(90)90255-r.
One hundred and sixty-six patients with advanced breast cancer previously not treated with chemotherapy for metastatic disease were randomly allocated to 20 mg Adriamycin i.v. weekly (Awkly) as bolus injection or 50 mg 4-epidoxorubicin biweekly over a 3-h infusion time (EPIbiwkly). Of the 149 patients evaluable for response, the response rate was 36% for Awkly vs. 22% for EPIbiwkly (P = 0.10). There was no difference in response duration or survival. The main difference between the two regimens was in toxicity. Seventy per cent of Awkly patients virtually had no side-effects vs. 15% in the EPIbiwkly group. Significant differences in favour of Awkly were observed both for nausea/vomiting and alopecia.
166例先前未接受过转移性疾病化疗的晚期乳腺癌患者被随机分为两组，一组接受每周静脉注射20mg阿霉素（每周阿霉素组），作为大剂量推注；另一组接受每两周静脉滴注50mg表阿霉素（表阿霉素组），滴注时间为3小时。在可评估疗效的149例患者中，每周阿霉素组的有效率为36%，表阿霉素组为22%（P = 0.10）。两组的缓解持续时间或生存期无差异。两种治疗方案的主要差异在于毒性。每周阿霉素组70%的患者几乎没有副作用，而表阿霉素组为15%。在恶心/呕吐和脱发方面，均观察到明显有利于每周阿霉素组的差异。
